Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Study to trace palliative treatment options for Metastatic triple negative breast cancer MTNBC patients who progress beyond second line chemotherapy through open discussions

Dr Joseph Kamugisha

A case presentation, of 42 year old premenopausal woman consulted at my clinic since since 2018 until present. She has family history of breast cancer in the family, her first line eldest maternal aunt died of breast cancer in 1998. She is HIV negative.She was diagnosed with a triple negative breast cancer. Ki 67 is 30%. Invasive ductal carcinoma type. T4B N3.The tumor/mass was too big to be resected with no presenting cormobities. Stage 3 C. Method. Prospective treatment with 1st line and 2nd line chemoregimens, follow-up and patient disease progressed to metastasis or stage 4 disease. Results. In June 2020,Patient in stable condition and no disease progression. The biggest point of discussion today is whether to combine a targeted therapy to nab paclitaxel or not to achieve better progression control results.